PTC Therapeutics | PTCT - Gewinn Vor Steuern

Aktienkurs
72.53
Täglich Wechseln
0.10 0.14%
Monatlich
9.20%
Jährlich
50.51%
Q2 Prognose
70.84




Gewinn Vor Steuern Veränderung Datum
Acadia Pharmaceuticals USD 26.32M 18.28M 2025-12
Alnylam Pharmaceuticals USD 161.14M 77.83M 2025-12
Amgen USD 3.92B 2.35B 2025-09
BioCryst Pharmaceuticals USD 248.02M 235.89M 2025-12
Biogen USD 557.3M 186.7M 2025-09
BioMarin Pharmaceutical USD -26.32M 324.19M 2025-09
Cytokinetics USD -183.03M 123.15M 2025-12
Daiichi Sankyo JPY 106.73B 48.96B 2025-12
Enanta Pharmaceuticals USD -22.71M 95.08M 2024-12
Esperion Therapeutics USD 63.67M 95M 2025-12
Gilead Sciences USD 3.64B 1.21B 2025-09
Incyte USD 389.94M 92.37M 2025-12
Ionis Pharmaceuticals USD -228M 99M 2025-12
Ironwood Pharmaceuticals USD 68.02M 30.2M 2025-09
Karyopharm Therapeutics USD -39.9M 9.01M 2025-12
Novartis USD 4.64B 445M 2025-12
Pfizer USD 3.33B 290M 2025-09
PTC Therapeutics USD -139.08M 116.01M 2025-12
Puma Biotechnology USD 20.61M 24.76M 2024-09
Roche Holding CHF 4.79B 3.01B 2025-06
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Sarepta Therapeutics USD -407.67M 213.63M 2025-12
TG Therapeutics USD 45.09M 19.18M 2025-12
Ultragenyx Pharmaceutical USD -128M 51.54M 2025-12
Vertex Pharmaceuticals USD 1.3B 15.8M 2025-09
Xencor USD -4.27M 1.76M 2025-12